Guideline adherence down for combination RT-ADT February 01, 2017 By Wayne Kuznar Adherence to guidelines for the use of combination radiation therapy and androgen deprivation therapy in the United States for the treatment of high-risk or locally advanced prostate cancer has decreased over time, according to data presented by Paolo Dell’Oglio, MD. Post-RT proctitis less likely in ACE inhibitor users February 01, 2017 By Wayne Kuznar High-grade proctitis after radical radiation therapy with neoadjuvant or adjuvant hormonal therapy is significantly less likely in patients taking angiotensin-converting-enzyme inhibitors. Major decline in prostate Bx rates follows PSA publications January 25, 2017 By Badar M. Mian MD “It is clear that in order to reduce the morbidity of PSA screening and early detection of prostate cancer, more needs to be done,” writes Badar M. Mian, MD. Studies reveal drop in PCa treatment, rise in metastatic disease Findings from two new studies provide insight on the impact of changing recommendations for prostate cancer screening and management. Bone metastases Tx: 12-week dosing interval appears feasible Results of a 2-year clinical trial support switching to a less frequent administration schedule when using zoledronic acid (Zometa) to prevent skeletal-related events in men with prostate cancer. Top 10 prostate cancer articles of 2016 December 13, 2016 These are Urology Times' most-read prostate cancer articles of 2016. Study examines link between inflammation, prostate Ca December 13, 2016 By Keith Loria Researchers at UCLA have discovered a previously unrecognized type of progenitor cell in inflamed areas of the prostate that have the ability to initiate cancer in response to genetic changes. Few prostate Ca patients with BCR develop metastasis December 01, 2016 By Wayne Kuznar Fewer than 20% of patients with biochemical recurrence after radical prostatectomy develop metastasis, and a smaller proportion die as a result of prostate cancer.